🔎 Trials Near Me

Home › Endometrial Cancer › North Carolina

Endometrial Cancer clinical trials in North Carolina

31 studies for Endometrial Cancer are looking for participants at sites in North Carolina.

Cities in North Carolina

Tirzepatide in Obesity-Driven Endometrial Cancer

  • Lineberger Comprehensive Cancer Center, Chapel Hill
RecruitingEarly phase 1
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07065552

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Cone Health MedCenter Asheboro, Asheboro
  • Cone Health Cancer Center at Alamance Regional, Burlington
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • and 8 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Duke University, Durham
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750

Distance-Based Exercise to Preserve Function and Prevent Disability

  • Novant Health Cancer Institute - Kernersville, Kernersville
  • Novant Health Cancer Institute - Mount Airy, Mount Airy
  • Novant Health Forsyth Medical Center, Winston-Salem
Recruiting
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07059884

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • Carolina Cancer Research Center, Wilson
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • Duke University Medical Center, Durham
  • and 3 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07198074

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  • Duke University Medical Center, Durham
  • Duke Women's Cancer Care Raleigh, Raleigh
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05112601

DESTINY-PANTUMOUR04

  • Research Site, Durham
  • Research Site, Wilson
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Duke University Medical Center, Durham
  • Duke Womens Cancer Care Raleigh, Raleigh
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT05640999

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  • Duke Cancer Institute ( Site 6049), Durham
  • FirstHealth of the Carolinas ( Site 6037), Pinehurst
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT06952504

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • UNC- Chapel Hill, Chapel Hill
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  • Research Site, Charlotte
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  • Atrium Health LCI - Morehead, Charlotte
  • Atrium Health LCI - Ballantyne, Charlotte
  • Atrium Health LCI - Concord, Concord
  • and 3 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 9, 2026 · NCT07166094

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

  • Duke Cancer Institute, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06515613

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  • Research Site, Charlotte
  • Research Site, Charlotte
  • Research Site, Winston-Salem
  • and 1 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06989112

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

  • Atrium Health - Wake Forest, Charlotte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07470853

FOG-001 in Locally Advanced or Metastatic Solid Tumors

  • Duke University, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264

A Study of PHST001 in Advanced Solid Tumors

  • Duke Cancer Institute, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06840886

A Study of DM002 in Patients With Advanced Solid Tumors

  • Carolina BioOncology Institute, LLC, Huntersville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06751329

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  • Research Site, Greenville
  • Research Site, Pinehurst
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 29, 2026 · NCT07044336

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

  • FirstHealth of the Carolinas, Inc., Pinehurst
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 28, 2026 · NCT07022483

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

  • Investigative Site #131, Raleigh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT06974110

The Better, Harder, Faster, Stronger Study

  • Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingObservational study
Ages 55 and older · Women · Updated Jul 15, 2026 · NCT07220512

Integrated Cancer Repository for Cancer Research

  • Cape Fear Valley Health System, Fayetteville
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

  • Carolina BioOncology Institute, Huntersville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT06993844

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

  • Lineberger Comprehensive Cancer Center, Chapel Hill
RecruitingPhase 1
Ages 18 and older · Women · Updated Jan 29, 2026 · NCT05542407

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

  • Dren Investigational Site, Huntersville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 7, 2026 · NCT06999187

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

  • Levine Cancer Institute, Charlotte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2025 · NCT05997017

Multimedia Aid for Genetic Testing in Gynecologic Oncology

  • Univeristy of North Carolina at Chapel Hill, Chapel Hill
Recruiting
Ages 18 and older · Women · Updated Nov 12, 2025 · NCT07084168

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Chapel Hill
  • Massive Bio SYNERGY-AI site, Winston-Salem
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  • FirstHealth Carolinas, Pinehurst
RecruitingPhase 2/3
Ages 18 and older · Women · Updated May 2, 2024 · NCT05797831

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.